JPWO2021062061A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021062061A5
JPWO2021062061A5 JP2022518762A JP2022518762A JPWO2021062061A5 JP WO2021062061 A5 JPWO2021062061 A5 JP WO2021062061A5 JP 2022518762 A JP2022518762 A JP 2022518762A JP 2022518762 A JP2022518762 A JP 2022518762A JP WO2021062061 A5 JPWO2021062061 A5 JP WO2021062061A5
Authority
JP
Japan
Prior art keywords
oral formulation
oral
denatonium
acid
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022518762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549833A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/052588 external-priority patent/WO2021062061A1/en
Publication of JP2022549833A publication Critical patent/JP2022549833A/ja
Publication of JPWO2021062061A5 publication Critical patent/JPWO2021062061A5/ja
Pending legal-status Critical Current

Links

JP2022518762A 2019-09-25 2020-09-24 経口速放出性医薬組成物および減量治療の方法 Pending JP2022549833A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905943P 2019-09-25 2019-09-25
US62/905,943 2019-09-25
PCT/US2020/052588 WO2021062061A1 (en) 2019-09-25 2020-09-24 Oral pharmaceutical immediate release composition and method of treatment for weight loss

Publications (2)

Publication Number Publication Date
JP2022549833A JP2022549833A (ja) 2022-11-29
JPWO2021062061A5 true JPWO2021062061A5 (no) 2023-10-02

Family

ID=75167128

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022518762A Pending JP2022549833A (ja) 2019-09-25 2020-09-24 経口速放出性医薬組成物および減量治療の方法

Country Status (8)

Country Link
US (1) US20220280457A1 (no)
EP (1) EP4034082A4 (no)
JP (1) JP2022549833A (no)
KR (1) KR20220106960A (no)
CN (1) CN114786647A (no)
AU (1) AU2020354634A1 (no)
CA (1) CA3151431A1 (no)
WO (1) WO2021062061A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022263996A1 (en) * 2021-04-27 2023-11-02 Aardvark Therapeutics, Inc. Combination of bitter receptor agonist and gut-signaling compound
CA3233038A1 (en) 2021-10-14 2023-04-20 Jeffrey OSTER Monohydrate salt of denatonium acetate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
KR20040063616A (ko) * 2003-01-08 2004-07-14 김원호 다이어트 식품용 조제
US8492312B2 (en) * 2005-11-10 2013-07-23 Regents Of The University Of Minnestoa Systemic plant conditioning composition
US8357398B2 (en) * 2009-10-21 2013-01-22 Alitair Pharmaceuticals Inc. Benzonatate compositions and methods of use
US8796233B2 (en) * 2010-06-17 2014-08-05 California Institute Of Technology Methods and systems for modulating hormones and related methods, agents and compositions
SG10201607085WA (en) * 2011-01-07 2016-10-28 Elcelyx Therapeutics Inc Chemosensory Receptor Ligand-Based Therapies
EP3138897A1 (en) * 2015-09-04 2017-03-08 The Procter and Gamble Company Films at least 80 microns thick comprising aversive agents, unit dose detergent articles wrapped therein, uses and methods related thereto
EP3138898A1 (en) * 2015-09-04 2017-03-08 The Procter and Gamble Company Water-soluble detergent articles wrapped in a film with an aversive agent mainly in the flanges or skirt thereof
EP3138900A1 (en) * 2015-09-04 2017-03-08 The Procter and Gamble Company Detergent compositions and wrapping films therefor having at least two different aversive agents and methods related thereto
WO2020014494A1 (en) * 2018-07-11 2020-01-16 Aardvark Therapeutics Inc. Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension

Similar Documents

Publication Publication Date Title
RU2493831C2 (ru) Фармацевтические композиции
EP2768479B1 (en) Excipients for nicotine-containing therapeutic compositions
JP5981416B2 (ja) ニコチン含有医薬組成物
AU2006220100B2 (en) Pharmaceutical forms with improved pharmacokinetic properties
CA2782734C (en) Nicotine containing formulation
US8153824B2 (en) Antidepressant oral liquid compositions
NO175131B (no) Fremgangsmåte for fremstilling av et harpiksadsorbat av ranitidin
JP2013528588A (ja) ニコチン含有医薬組成物
EP1965781A1 (en) Pharmaceutical formulation for sulfur-containing drugs in liquid dosage forms
TW201041607A (en) Orally disintegrating tablet compositions comprising combinations of non-opioid and opioid analgesics
EP2005945A9 (en) Oseltamivir phosphate granule and preparation mehtod thereof
RU2671491C2 (ru) Комплексная гранулированная композиция, обладающая улучшенной стабильностью, включающая левоцетиризин и монтелукаст
AU2008320458A1 (en) Stabilized pediatric suspension of carisbamate
CA2870130A1 (en) Compositions and methods for treating cough
MXPA98010007A (es) Comprimido de maleato de trimebutian en forma de pelicula.
CN107530294B (zh) 含有质子泵抑制剂的肠溶包衣丸剂
JP2022549833A (ja) 経口速放出性医薬組成物および減量治療の方法
WO2000066169A1 (en) Pharmaceutical formulations
JPWO2021062061A5 (no)
RU2240784C1 (ru) Лекарственное средство на основе арбидола
EP2481395A1 (en) Sachet, effervescent tablet and dry syrup of otilonium
EP3968955A1 (en) Pharmaceutical oral liquid solution of ivacaftor
US20080008772A1 (en) Narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
JPH10511637A (ja) ヒスタミンｈ▲下２▼−アンタゴニストの吸収を増強するためのグルコースのようなパラセルラー吸収エンハンサーの使用
EP3095466A1 (en) Pharmaceutical formulations with improved solubility and stability